Airain ltd reduced its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 52.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 310,487 shares of the company’s stock after selling 346,407 shares during the period. Airain ltd’s holdings in Teva Pharmaceutical Industries Limited were worth $10,314,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of TEVA. Bronfman E.L. Rothschild L.P. increased its position in Teva Pharmaceutical Industries Limited by 7.8% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 3,617 shares of the company’s stock worth $116,000 after buying an additional 261 shares in the last quarter. Kistler Tiffany Companies LLC increased its position in Teva Pharmaceutical Industries Limited by 74.7% in the second quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock worth $122,000 after buying an additional 1,571 shares in the last quarter. FNY Managed Accounts LLC bought a new position in Teva Pharmaceutical Industries Limited during the first quarter worth $123,000. Sterling Investment Advisors Ltd. increased its position in Teva Pharmaceutical Industries Limited by 2.6% in the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock worth $125,000 after buying an additional 100 shares in the last quarter. Finally, Cutler Capital Management LLC bought a new position in Teva Pharmaceutical Industries Limited during the second quarter worth $133,000. 56.04% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded down 0.48% during mid-day trading on Friday, hitting $16.21. 11,590,321 shares of the stock traded hands. Teva Pharmaceutical Industries Limited has a 12 month low of $15.85 and a 12 month high of $52.66. The company’s market cap is $16.47 billion. The company’s 50 day moving average is $25.37 and its 200 day moving average is $30.35.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.06 by $0.07. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The business had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. During the same period last year, the firm earned $1.25 EPS. The company’s revenue for the quarter was up 12.9% compared to the same quarter last year. On average, analysts expect that Teva Pharmaceutical Industries Limited will post $4.32 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 14th. Shareholders of record on Tuesday, August 29th will be paid a dividend of $0.085 per share. The ex-dividend date of this dividend is Friday, August 25th. This represents a $0.34 annualized dividend and a yield of 2.10%. Teva Pharmaceutical Industries Limited’s dividend payout ratio (DPR) is presently -14.22%.

COPYRIGHT VIOLATION WARNING: This story was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://www.thecerbatgem.com/2017/08/26/teva-pharmaceutical-industries-limited-teva-stake-reduced-by-airain-ltd.html.

A number of research analysts have recently weighed in on the stock. Credit Suisse Group downgraded shares of Teva Pharmaceutical Industries Limited from a “neutral” rating to an “underperform” rating and reduced their target price for the company from $25.00 to $13.00 in a research report on Wednesday. Mizuho reissued a “neutral” rating and set a $16.00 target price (down from $30.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Tuesday. BidaskClub downgraded shares of Teva Pharmaceutical Industries Limited from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 16th. Citigroup Inc. downgraded shares of Teva Pharmaceutical Industries Limited from a “buy” rating to a “neutral” rating and reduced their target price for the company from $32.00 to $19.00 in a research report on Wednesday, August 16th. Finally, Zacks Investment Research downgraded shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “strong sell” rating in a research report on Wednesday, August 9th. Four research analysts have rated the stock with a sell rating, twenty have assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $35.06.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Stock Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related stocks with our FREE daily email newsletter.